Bruce E. Johnson

TL;DR: A novel, highly sensitive IHC assay reliably detects lung adenocarcinomas with ALK rearrangements and obviates the need for fluorescence in situ hybridization analysis for the majority of cases, and therefore could be routinely applicable in clinical practice to detect lung cancers that may be responsive to ALK inhibitors.

TL;DR: The frequency of EGFR mutations, their impact on NSCLC biology, clinical treatment, and clinical trial design, as well as methods and limitations for mutation detection, will be reviewed.

TL;DR: To discover genes involved in von Hippel-Lindau (VHL)-mediated carcinogenesis, renal cell carcinoma cell lines stably transfected with wild-type VHL-expressing transgenes were used and large-scale RNA differential display technology applied to identify several differentially expressed genes.

TL;DR: The addition of vandetanib to docetaxel provides a significant improvement in PFS in patients with advanced NSCLC after progression following first-line therapy, supported investigation of the combination in this larger, definitive phase 3 trial (ZODIAC).

TL;DR: In this paper, the impact of epidermal growth factor receptor (EGFR) and KRAS genotypes on outcomes with erlotinib or gefitinib therapy continues to be debated.